emd-1204831
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2010 (NCT01110083)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Hepatocyte growth factor receptorINHIBITOR
MET inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cn1cc(-c2ccc(=O)n(Cc3cccc(-c4ncc(OCCN5CCOCC5)cn4)c3)n2)cn1- Mol. weight
- 473.54 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3960488 ↗
- ChEMBLCHEMBL3545053 ↗
Also known as
- 4-(2-(2-(3-(3-(1-methyl-1h-pyrazol-4-yl)-6-oxo-1,6-dihydropyridazin-1-ylmethyl)phenyl)pyrimidin-5-yloxy)ethyl)morpholine
- emd 1204831
- emd 1204831
- emd 1204831
- emd-1204831
- emd-1204831
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01110083 | Phase 1 | Apr 1, 2010 | Merck KGaA, Merck Serono |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck KGaA | For profit | 1 | 0 | 1 | 2010 |
| Merck Serono | For profit | 1 | 1 | 1 | 2010 |
2 organizations
Page 1 / 1